Clozapine Rechallenge Following Neuroleptic Malignant Syndrome

@article{Lally2019ClozapineRF,
  title={Clozapine Rechallenge Following Neuroleptic Malignant Syndrome},
  author={J. Lally and C. McCaffrey and Conall O'Murchu and A. Krivoy and A. Gu{\'e}randel and J. MacCabe and F. Gaughran},
  journal={Journal of Clinical Psychopharmacology},
  year={2019},
  volume={39},
  pages={372 - 379}
}
  • J. Lally, C. McCaffrey, +4 authors F. Gaughran
  • Published 2019
  • Psychology, Medicine
  • Journal of Clinical Psychopharmacology
  • Supplemental digital content is available in the text. Abstract Purpose/Background Neuroleptic malignant syndrome (NMS) has been described with most antipsychotics, most commonly first generation. Clozapine has also been associated with NMS. Methods/Procedures We conducted a systematic review to identify all studies investigating or describing (a) clozapine rechallenge following suspected NMS associated with clozapine, (b) clozapine use after suspected NMS associated with another antipsychotic… CONTINUE READING

    Topics from this paper.